RNA Nanoparticle Motion Elements for Targeted Drug Delivery

The patent applies local quality by functionalizing nanoparticles with specific ligands (antibodies, peptides, aptamers, or small molecules) that recognize and bind to receptors overexpressed on tumor cells. This creates localized high-affinity binding at the tumor site while maintaining low affinity elsewhere in the body, enabling high therapeutic efficacy at the target with reduced systemic toxicity and side effects.

The patent uses ligand-functionalized nanoparticles as intermediaries to deliver therapeutic drugs specifically to tumor cells. The ligand-nanoparticle-drug complex acts as a mediator that transports the therapeutic agent from systemic circulation directly to the target cells through receptor-mediated endocytosis, improving efficacy while reducing the need for high systemic doses that cause toxicity.

The patent segments the nanoparticle structure into distinct functional domains: a stable core structure that maintains nanoparticle integrity and a surface layer where ligands are conjugated. This segmentation allows the core to remain stable while the surface is optimized for high-affinity tumor targeting through ligand-receptor interactions, resolving the contradiction between stability and targeting affinity.

The patent uses linker molecules as intermediaries between the nanoparticle surface and the targeting ligands. These linkers provide stable attachment points for ligands while maintaining the structural integrity of the nanoparticle. The intermediary linkers allow high-affinity binding to tumor receptors without compromising the stability of the nanoparticle core composition.